000164096 001__ 164096
000164096 005__ 20240229133512.0
000164096 0247_ $$2doi$$a10.1158/1055-9965.EPI-20-0855
000164096 0247_ $$2pmid$$apmid:33082206
000164096 0247_ $$2ISSN$$a1055-9965
000164096 0247_ $$2ISSN$$a1538-7755
000164096 0247_ $$2altmetric$$aaltmetric:92803958
000164096 037__ $$aDKFZ-2020-02242
000164096 041__ $$aeng
000164096 082__ $$a610
000164096 1001_ $$00000-0002-0442-3284$$aAglago, Elom Kouassivi$$b0
000164096 245__ $$aSoluble Receptor for Advanced Glycation End-products (sRAGE) and colorectal cancer risk: a case-control study nested within a European prospective cohort.
000164096 260__ $$aPhiladelphia, Pa.$$bAACR$$c2021
000164096 3367_ $$2DRIVER$$aarticle
000164096 3367_ $$2DataCite$$aOutput Types/Journal article
000164096 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611325805_7173
000164096 3367_ $$2BibTeX$$aARTICLE
000164096 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164096 3367_ $$00$$2EndNote$$aJournal Article
000164096 500__ $$a2021 Jan;30(1):182-192
000164096 520__ $$aOverexpression of the Receptor for Advanced Glycation End-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer (CRC) risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation.To investigate whether sRAGE and related genetic variants are associated with CRC risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 CRC matched case-control sets. Twenty-four single nucleotide polymorphisms (SNPs) encoded in the genes associated with sRAGE concentrations were available for 1,985 CRC cases and 2,220 controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional and unconditional logistic regression for CRC risk and circulating sRAGE and SNPs, respectively.Higher sRAGE concentrations were inversely associated with CRC (ORQ5vs.Q1=0.77, 95%CI=0.59-1.00). Sex-specific analyses revealed that the observed inverse risk association was restricted to men (ORQ5vs.Q1=0.63, 95%CI=0.42-0.94) whereas no association was observed in women (ORQ5vs.Q1=1.00, 95%CI=0.68-1.48, Pheterogeneity for sex=0.006). Participants carrying minor allele of rs653765 (promoter region of ADAM10) had lower CRC risk (C vs. T, OR=0.90; 95%CI=0.82-0.99).Pre-diagnostic sRAGE concentrations were inversely associated with CRC risk in men but not in women. A SNP located within ADAM10 gene pertaining to RAGE shedding, was associated with CRC risk.Further studies are needed to confirm our observed sex difference in the association and better explore the potential involvement of genetic variants of sRAGE in CRC development.
000164096 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000164096 588__ $$aDataset connected to CrossRef, PubMed,
000164096 7001_ $$aRinaldi, Sabina$$b1
000164096 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b2
000164096 7001_ $$aJiao, Li$$b3
000164096 7001_ $$00000-0003-1668-8770$$aHughes, David J$$b4
000164096 7001_ $$00000-0002-7805-9913$$aFedirko, Veronika$$b5
000164096 7001_ $$aSchalkwijk, Casper G$$b6
000164096 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b7
000164096 7001_ $$00000-0003-0481-2893$$aDahm, Christina C$$b8
000164096 7001_ $$aOvervad, Kim$$b9
000164096 7001_ $$aEriksen, Anne Kirstine$$b10
000164096 7001_ $$00000-0002-9083-8960$$aKyrø, Cecilie$$b11
000164096 7001_ $$00000-0002-5956-5693$$aBoutron-Ruault, Marie-Christine$$b12
000164096 7001_ $$00000-0002-6927-3360$$aRothwell, Joseph A$$b13
000164096 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b14
000164096 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b15$$udkfz
000164096 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b16$$udkfz
000164096 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b17
000164096 7001_ $$aAleksandrova, Krasimira$$b18
000164096 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b19
000164096 7001_ $$00000-0003-0122-8624$$aKrogh, Vittorio$$b20
000164096 7001_ $$aPanico, Salvatore$$b21
000164096 7001_ $$00000-0003-2666-414X$$aTumino, Rosario$$b22
000164096 7001_ $$00000-0001-5774-0905$$aNaccarati, Alessio$$b23
000164096 7001_ $$aBueno-de-Mesquita, Bas$$b24
000164096 7001_ $$avan Gils, Carla H$$b25
000164096 7001_ $$aSandanger, Torkjel M$$b26
000164096 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b27
000164096 7001_ $$00000-0003-2476-4251$$aSkeie, Guri$$b28
000164096 7001_ $$aQuirós, J Ramón$$b29
000164096 7001_ $$aJakszyn, Paula$$b30
000164096 7001_ $$00000-0003-4817-0757$$aSánchez, Maria-Jose$$b31
000164096 7001_ $$aAmiano, Pilar$$b32
000164096 7001_ $$00000-0002-9637-3869$$aHuerta, José María$$b33
000164096 7001_ $$00000-0001-8434-2013$$aArdanaz, Eva$$b34
000164096 7001_ $$aJohansson, Ingegerd$$b35
000164096 7001_ $$00000-0001-8540-6891$$aHarlid, Sophia$$b36
000164096 7001_ $$00000-0002-5652-356X$$aPerez-Cornago, Aurora$$b37
000164096 7001_ $$00000-0001-9635-0416$$aMayén, Ana-Lucia$$b38
000164096 7001_ $$aCordova, Reynalda$$b39
000164096 7001_ $$aGunter, Marc J$$b40
000164096 7001_ $$aVineis, Paolo$$b41
000164096 7001_ $$00000-0002-0893-2377$$aCross, Amanda J$$b42
000164096 7001_ $$aRiboli, Elio$$b43
000164096 7001_ $$aJenab, Mazda$$b44
000164096 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-20-0855$$gp. cebp.0855.2020 -$$n1$$p182-192$$tCancer epidemiology, biomarkers & prevention$$v30$$x1538-7755$$y2021
000164096 909CO $$ooai:inrepo02.dkfz.de:164096$$pVDB
000164096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000164096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000164096 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000164096 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000164096 9141_ $$y2021
000164096 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-17
000164096 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000164096 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000164096 980__ $$ajournal
000164096 980__ $$aVDB
000164096 980__ $$aI:(DE-He78)C020-20160331
000164096 980__ $$aUNRESTRICTED